Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.81
+0.2%
$0.71
$0.38
$215.31
$9.18M0.711.03 million shs106,562 shs
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
$0.49
+4.2%
$4.04
$3.36
$26.30
$4.60M1.51628,703 shs181,967 shs
iBio, Inc. stock logo
IBIO
iBio
$0.74
+1.1%
$0.81
$0.64
$6.89
$12.14M0.94875,162 shs231,923 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs21,256 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
+3.58%-2.94%+8.87%+100.00%-99.50%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00%-3.51%-10.96%+33.52%-52.77%
iBio, Inc. stock logo
IBIO
iBio
-0.59%-4.38%-5.75%+3.81%-66.20%
ObsEva SA stock logo
OBSV
ObsEva
0.00%-75.00%-75.00%-75.00%-75.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
2.6719 of 5 stars
3.52.00.00.00.61.71.9
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
1.4554 of 5 stars
3.50.00.00.01.10.00.6
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
3.00
Buy$360.0044,234.98% Upside
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00
N/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
3.00
Buy$5.00580.27% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AZRX, IBIO, AEON, and OBSV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
5/5/2025
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/A($4.12) per shareN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/A($0.76) per shareN/A
iBio, Inc. stock logo
IBIO
iBio
$375K32.38N/AN/A$1.41 per share0.52
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-$36.63M$298.124.51N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/A
iBio, Inc. stock logo
IBIO
iBio
-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/A
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest AZRX, IBIO, AEON, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025N/A
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-$11.51N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/A
0.22
0.22
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/A
1.33
1.33
iBio, Inc. stock logo
IBIO
iBio
0.05
1.76
1.76
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
22.78%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
6.27%
iBio, Inc. stock logo
IBIO
iBio
7.90%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
0.86%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
7.30%
iBio, Inc. stock logo
IBIO
iBio
0.58%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
511.31 million74.37 millionNot Optionable
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
129.33 million8.65 millionNot Optionable
iBio, Inc. stock logo
IBIO
iBio
10016.52 million9.82 millionN/A
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva Announces Update on Board of Directors
ObsEva SA OBSN
ObsEva SA OBSEF
ObsEva (NASDAQ: OBSV)
ObsEva Annual Report 2022 - Marketscreener.com
ObsEva Annual Report 2022 - Yahoo Finance
ObsEva Annual Report 2022 - Benzinga
ObsEva Annual Report 2022 - EIN News

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON Biopharma stock logo

AEON Biopharma NASDAQ:AEON

$0.81 +0.00 (+0.25%)
Closing price 03:58 PM Eastern
Extended Trading
$0.80 -0.01 (-0.99%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

AzurRx BioPharma stock logo

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

iBio stock logo

iBio NYSE:IBIO

$0.74 +0.01 (+1.14%)
Closing price 03:58 PM Eastern
Extended Trading
$0.73 0.00 (-0.14%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.